A phase IIIb, multi-center, stratified, open-label study to evaluate the immunogenicity, steady state trough level, and safety of subcutaneous abatacept (BMS-188667) in subjects with rheumatoid arthritis administered with or without background methotrexate

Trial Profile

A phase IIIb, multi-center, stratified, open-label study to evaluate the immunogenicity, steady state trough level, and safety of subcutaneous abatacept (BMS-188667) in subjects with rheumatoid arthritis administered with or without background methotrexate

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs Abatacept (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Results presented at 2009 Annual Scientific Meeting of the American College of Rheumatology, according to a BristolMyers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top